AbbVie has announced data from its Phase III CANOVA study, which evaluated the safety and efficacy of venetoclax plus dexamethasone for patients with t(11;14)-positive relapsed or refractory multiple myeloma. The results did not show a significant improvement in progression-free survival compared to pomalidomide plus dexamethasone. However, secondary endpoints such as overall response rate and rate of very good partial response or better showed favorable results for the VenDex combination. The safety profile of the combination was consistent with known profiles for the individual drugs. AbbVie plans to discuss the data with health authorities to further understand the potential of venetoclax as a biomarker-driven therapy in multiple myeloma. Read the full press release to learn more.